Profound Medical Corp. (PROF)
NASDAQ: PROF · Real-Time Price · USD
6.01
-0.30 (-4.75%)
At close: Oct 16, 2026, 4:00 PM EDT
6.00
-0.01 (-0.17%)
After-hours: Oct 16, 2026, 7:30 PM EDT
Profound Medical Revenue
Profound Medical had revenue of $2.48M in the quarter ending June 30, 2026, with 12.30% growth. This brings the company's revenue in the last twelve months to $19.09M, up 119.30% year-over-year. In the year 2025, Profound Medical had annual revenue of $16.10M with 50.73% growth.
Revenue (ttm)
$19.09M
Revenue Growth
+119.30%
P/S Ratio
11.56
Revenue / Employee
$117,815
Employees
162
Market Cap
220.56M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.10M | 5.42M | 50.73% |
| Dec 31, 2024 | 10.68M | 3.48M | 48.35% |
| Dec 31, 2023 | 7.20M | 518.00K | 7.75% |
| Dec 31, 2022 | 6.68M | -192.00K | -2.79% |
| Dec 31, 2021 | 6.87M | -431.00K | -5.90% |
| Dec 31, 2020 | 7.30M | 3.13M | 74.99% |
| Dec 31, 2019 | 4.17M | 2.26M | 117.58% |
| Dec 31, 2018 | 1.92M | -1.98M | -50.81% |
| Dec 31, 2017 | 3.90M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Treace Medical Concepts | 205.31M |
| InfuSystem Holdings | 143.34M |
| RxSight | 127.58M |
| Standard BioTools | 84.60M |
| Electromed | 73.78M |
| Mobia Medical | 45.28M |
| TriSalus Life Sciences | 45.08M |
| ClearPoint Neuro | 42.28M |
PROF News
- 4 days ago - TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity - Financial Post
- 4 days ago - TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity - GlobeNewsWire
- 9 days ago - Profound Medical, Telix Pharma Sign Co-Education Deal To Advance PSMA-Informed Prostate Care - Nasdaq
- 9 days ago - Profound Medical enters co-education agreement with Telix Pharmaceuticals - TheFly
- 9 days ago - Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care - GlobeNewsWire
- 9 days ago - Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength? - Nasdaq
- 10 days ago - Profound Medical (PROF) Surges 17.1% Pre-Market Amid Broader Market Uncertainty - GuruFocus
- 10 days ago - Profound Medical (PROF) Projects Strong Q3 Revenue Growth, Shares Jump 16% - GuruFocus